Drug Profile
Fiacitabine
Alternative Names: FIAC; FOACLatest Information Update: 10 Jan 2001
Price :
$50
*
At a glance
- Originator Memorial Sloan-Kettering Cancer Center
- Developer Memorial Sloan-Kettering Cancer Center; Oclassen Pharmaceuticals
- Class Antivirals; Arabinonucleosides; Pyrimidinones; Small molecules
- Mechanism of Action DNA-directed DNA polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cytomegalovirus infections; Herpes simplex virus infections
Most Recent Events
- 10 Jan 2001 Discontinued-II for Cytomegalovirus infections in USA (PO)
- 10 Jan 2001 Discontinued-II for Herpes simplex virus infections in USA (PO)
- 29 Sep 1998 No-Development-Reported for Herpes simplex virus infections in USA (PO)